期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

丙型肝炎病毒高变区准种异质性与干扰素疗效的关系

The heterogeneity of HCV quasi-species in the hypervariable region and its relationship to interferon therapy
原文传递
导出
摘要 丙型肝炎病毒(HCV)基因组具有高度的变异性,在机体内以准种的形式存在[1,2],尤其以E2/NS1区384～410和474～480位氨基酸变异程度最高,分别称为HVR1和HVR2.近年的研究发现,HCV准种感染除与引起HCV感染慢性化有关外,还与HCV对干扰素(IFN)治疗的抵抗作用关系密切.
作者 石理兰 张琳 赵桂珍 乔光彦
机构地区 中国医科大学第二临床学院感染科
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2005年第7期523-523,527,共2页 Chinese Journal of Hepatology
基金 辽宁省教育厅资助(202013120)
关键词 丙型肝炎病毒 高变区 准种异质性 干扰素 HCV 基因组 Hepacivirus Interferon-alpha
分类号 R512.63 [医药卫生—内科学]
  • 相关文献

参考文献4

  • 1Hino K, Yamaguchi Y, Fujiwara D, et al. Hepatitis C virus quasispecies and response to interferon therapy in patients with chronic hepatitis C: a prospective study. J Viral Hepat, 2000, 7: 36-42.
  • 2Ambrosch A, Konig W. Characteristics of the hepatitis C virus and viral predictors of therapeutic response. Med Klin, 1999, 94: 626-632.
  • 3张琳,赵桂珍,李颖,石理兰.慢型丙型肝炎患者干扰素治疗前后HCV HVR1准种的动态变化[J].世界华人消化杂志,2003,11(2):182-184. 被引量：6
  • 4Sandres K, Dubois M, Pasquier C, et al. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol, 2000, 74:661-668.

二级参考文献30

  • 1Honda M, Kaneko S,Sakai A,Unoura M, Murakami S,KobayashiK.Degree of diversity of hepatitis C virus quasispecies and progression of liver disease.Hepatology 1994;20:1144-1151
  • 2Sakai A,Kaneko S,Honda M,Matsushta E,Kobayashi K.Quasispecies of hepatitis C virus in serum and three different parts of the liver of patients with chronic hepatitis.Hepatology 1999;30:556-561
  • 3Koizumi K,Enomoto N,Kurosaki M,Murakami T,Izumi N, Marumo F,Sato C.Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment.Hepatology 1995;22:30-35
  • 4Gonzale RP ,Qian K,Jan Y,Davis GL, Ohno T, Mizokami M,Lau Z.Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C.J Med Virol 1996;49:242-247
  • 5Shirai M, Arichi T, Nishioka M, Nomura T, Ikeda K,Kawanishi K, Engelhard V, Feistone S, Berzofsky JA. CTL responses of HLAA2.1-Transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of human carrying HLA-A2.1. J Immunol1995;154:2733-2742
  • 6Farci P, Shimoda A, Wong D, Cabezon T, Gioannis D, Strazzera A, Shimizu Y, Shapiro M, Alter HJ, Purcell RH. Prevention of hepatitis C virus infection in chimpanzees by heperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Nalt Acad Sci USA 1996;93:15394-15399
  • 7Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH, Yoshikura H. A hyperimmune serum against a synthetic peptidecorresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996;223:409-412
  • 8Allain JP, Zhai W, Shang D, Timmers E, Alexander G. Hypervariable region diversity of hepatitis C virus and humoral response:comparision between patients with or without cirrhosis.J Med Virol 1999;59:25-31
  • 9Maetell M, Esteban J, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J.Hepatitis C virus (HCV) circulates as a population of different but closely related genomes:quasispecies nature of HCV genome distribution. J Virol1992;66:3225-3229
  • 10Polyak SJ, Gerotto M. The molecular basis for responsiveness to anti-viral therapy in hepatitis C. Form(Genova) 2000;10:46-58

共引文献5

中华肝脏病杂志
2005年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部